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Background: Vitamin D is essential for calcium metabolism, Vitamin D deficiency can precipitate osteoporosis,
cause muscle weakness and increase the risk of fracture. The aim of this study was to assess the prevalence of
vitamin D inadequacy among non-supplemented postmenopausal women with osteoporosis and fragility fractures
of the hip or vertebrae in Taiwan.
Methods: This multi-center, cross-sectional, observational study analyzed the vitamin D inadequacy [defined as 25
(OH) D level less than 30 ng/mL] in Taiwanese postmenopausal osteoporotic patients who suffered from a low
trauma, non-pathological fragility hip or vertebral fracture that received post-fracture medical care when admitted
to hospital or at an outpatient clinic.
Results: A total of 199 patients were enrolled at 8 medical centers in Taiwan; 194 patients met the study criteria
with 113 (58.2%) and 81 (41.8%) patients diagnosed with hip and vertebral fracture, respectively. The mean serum
25(OH) D level was 21.1 ± 9.3 ng/mL, resulting in a prevalence of vitamin D inadequacy of 86.6% of the patients.
Conclusions: High prevalence of vitamin D inadequacy across all age groups was found among non-supplemented
women with osteoporosis and fragility hip or vertebral fracture in Taiwan.
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Osteoporosis is a progressive systemic bone disease cha-
racterized by low bone mass and microarchitecture deteri-
oration of bone tissue, leading to increased bone fragility
and susceptibility to fracture. It is recognised as a major
public health problem in many countries, as well as in
Taiwan [1,2]. The fractures associated with osteoporosis
cause physical disability, reduced quality of life and high
mortality in the aging population [3,4]. Several therapeutic
options are available for the treatment or prevention of
osteoporosis [5,6], and some of these drugs were proven
to be efficacious and safe in Taiwanese population studies
[7-10]. Among the osteoporosis management factors,* Correspondence: chenjf56090@gmail.com
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unless otherwise stated.vitamin D plays an important role [11,12]. Vitamin D is
absorbed from food or synthesized in skin that is exposed
to sunlight. The liver converts it to 25-hydroxyvitamin D
[25(OH) D], which in turn is converted by the kidney to
active form calcitriol 1,25 (OH)2D. Vitamin D increases
serum calcium by promoting intestinal calcium absorption
and plays a role in bone formation and resorption [13].
Synthesis of 1, 25-dihydroxyvitamin D [1, 25(OH)2 D] is
stimulated by both PTH and hypophosphatemia. Vitamin
D deficiency is associated with secondary hyperparathyr-
oidism, which stimulates bone resorption, thus increasing
the rate of bone loss and the risk of fractures [14]. In
addition, vitamin D deficiency is associated with muscle
weakness and postural instability, leading to an increased
risk of falls [15], which may lead to fractures. However,
vitamin D status associated with fractures has not been in-
vestigated in the Taiwanese population. The objective of
this study was to evaluate the prevalence of vitamin DLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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porosis and fragility fractures of the hip or vertebrae in
Taiwan.Methods
Study design
This multi-center, cross-sectional, observational study was
conducted in 8 medical centers in Taiwan. Among hip frac-
ture patients, only those requiring hospitalization for post-
fracture medical treatment were enrolled in this study
while vertebral fracture patients were enrolled from an out-
patient clinic, for a 12-month period between September 1,
2010 and September 1, 2011. The study protocol was
approved by the Institutional Review Board of Chang
Gung Memorial Hospital Linkou and Kaohsiung, National
Taiwan University Hospital, Kaohsiung Medical University
Chung-Ho Memorial Hospital, Changhua Christian
Hospital, Chung Shan Medical University Hospital, Shin
Kong Wu Ho-Su Memorial Hospital, and Taipei Veterans
General Hospital, prior to initiation of the study and all
patients gave written informed consent before any study
procedure was performed. The study was conducted in
compliance with the current revision of the Helsinki
Declaration and in accordance with the Good Clinical
Practice guidelines.Study subjects
The centers recruited postmenopausal women aged 50
years and over with a recent low-trauma fragility vertebral
fracture at outpatient clinic or hip fracture inpatient care.
Low-trauma fractures were defined as fractures resulting
from falls from standing height. Recent fracture was de-
fined as hip fracture or related clinical signs/symptoms oc-
curring within 30 days of the study enrollment date;
vertebral fracture or related clinical signs/symptoms oc-
curring within 3 months of the study enrollment date.
Fracture was confirmed by radiograph or X-ray report;
categorization of vertebral fracture was assessed centrally.
Patients who had secondary osteoporosis or other dis-
eases which could affect bone metabolism, significant
hepatic or renal diseases [defined as serum alanine ami-
notransferase (ALT) > 3 times upper limit of normal
(ULN), and creatinine (Cr) > 1.6 mg/dL], malignant neo-
plasm, major trauma (e.g. automobile accident) or recent
use of drugs known to affect bone metabolism were ex-
cluded. Patients who participated in a clinical trial for
osteoporosis within the past 3 years, had low trauma
fracture of sites other than the hip or vertebrae, mentally
or legally incapacitated or unable to answer health-
related questions were also excluded as well as patients
with premature or surgical menopause, e.g. oophorec-
tomy due to ovarian cancer, or patients who have regu-
larly been receiving 2800 IU vitamin D supplement perweek or 400 IU vitamin D supplement per day at study
enrollment.Study procedures
Patients were required to have a physical examination,
lateral radiographs of the thoracic and lumbar spine for
vertebral fracture patients group, documentation of past
medical history and concomitant medications that affect
vitamin D metabolism, any use of anti-osteoporotic ther-
apies, pre-fracture daily activity and health-related ques-
tionnaire. A single, non-fasting blood sample to assess
25 (OH) D and other biochemical tests were performed
in the study visit. Vitamin D inadequacy was defined as
serum 25 (OH) D level less than 30 ng/mL. Considering
prior vitamin D studies definitions [12,16-18], we further
dissected vitamin D inadequacy into insufficiency as 25
(OH) D 10 to 30 ng/mL and deficiency as 25(OH) D <
10 ng/mL. In addition to this, a cut-point of 25 (OH) D
less than 20 ng/mL was also analyzed to allow compari-
son with some recent studies.
The radiographs were performed according to a stan-
dardized protocol. A visual semiquantitative grading of
vertebral fractures was performed, based on the criteria
of Genant et al., by a radiologist in a centralized way.
Bone mineral density (BMD) measured by dual energy
X-ray absorptiometry of lumbar spine and/or hip were
recorded.
Biochemical measurements were standardized using
central laboratory tests method.
Serum calcium, phosphate, and creatinine were mea-
sured by automated standard laboratory methods. Intact
PTH (i-PTH) was measured by ADVIA Centaur chemillu-
minescence instruments (SIEMENS Healthcare, Tarrytown,
New York), 25-OH Vitamin D Total by chemillumines-
cence (Diasorin, MN, USA). The inter-assay variations for
the three-level controls for assays i-PTH were 6.55%,
6.02% and 5.0%, and 25 (OH) D two level controls 6.06%
and 6.15%, respectively. Bone turnover markers were mea-
sured in all patients with Bone Alkaline Phosphatase
(BAP), by chemilluminescence using Beckman Access II
(Fullerton, California) with inter-assay variations for the
markers were 4.62% and 5.13%.Statistical analysis
Data management and analysis were performed using
the SAS 8.2 (SAS Institute Inc., Cary, NC, USA) and
SPSS 20.0 (IBM., USA). The prevalence of vitamin D in-
adequacy was analyzed; insufficiency and deficiency were
also summarized. Age and fracture site stratified preva-
lence of vitamin D insufficiency and deficiency were also
calculated. Data were presented as mean ± SD for con-
tinuous variables, the number and the proportions were
shown for categorical variables.
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variance (ANOVA) were used to examine the differences
between/among groups for continuous variables upon
the data distribution, and chi-square test or Fisher’s
exact test were used for categorical variables. Meanwhile,
Pearson correlation was used to assess the correlation
between serum vitamin D levels versus fracture risk fac-
tors in these patients. All significance tests were two-
tailed with p = 0.05.
Results
A total of 199 subjects were evaluated for inclusion with
194 subjects meeting all of the eligibility criteria as
shown in Figure 1. Five subjects were excluded due to
renal or liver impairment (4 subjects with Cr > 1.6 mg/
dL and 1 subject with ALT > 3 times ULN). The demo-
graphics and characteristics of the patients are shown in
Table 1. Overall, the average age was 77.6years (range:
52 to 103 years) and the mean BMI was 23.9 kg/m2. The
mean years since menopause were 27.4 with a minimum
of 5 years and maximum of 51 years. There was no dif-
ference of BMD at any site between the hip and verte-
bral fractures group.
The patient characteristics showed little difference be-
tween the hip and vertebral fracture group. Among 113
hip and 81 vertebral fracture women, the average age wasFigure 1 Patient distribution in the study.79.5years in hip fracture women while it was 74.6 years in
vertebral fracture women. Regarding the co-morbidity sur-
vey, only hypertension revealed a statistical difference (p =
0.033) between the groups, with 63.7% of the hip fracture
women diagnosed with hypertension compared to 51.9%
of the vertebral fracture group. Also, food composition in
terms of daily vitamin D source showed some differences
between groups. Among several types of calcium-rich and
vitamin-containing food, including milk, yolk, cod-liver
oil, fatty fish, and mushroom, the hip fracture group had
higher proportion of women taking cod-liver oil and eat-
ing more fatty fish and mushrooms (46.9% vs. 27.2%) than
the vertebral fracture group.
Overall, the mean level of 25(OH) D was 21.1 ±
9.3 ng/mL, ranging from 4.0 to 57.5 ng/mL (median: 20.0,
Q1:15.7, Q3:26.2). The prevalence of vitamin D inad-
equacy with serum 25(OH) D level lower than 30 ng/mL
was 86.6% of the subjects. Further dissection, vitamin D
insufficiency [25(OH) D 10–30 ng/mL] prevalence was
77.8% while vitamin D deficiency [25(OH) D < 10 ng/mL]
was 8.8% of the subjects (Table 2). Additionally, when
using another cut-off point of 25(OH) D < 20 ng/mL, the
prevalence was 49.5%, as shown in Table 3.
There was no statistically significant difference in the
mean 25(OH) D levels between hip and vertebral fractures
subjects, 20.5 vs. 22.0 ng/mL, respectively (p = 0.279;
Table 1 Patients’ characteristics
Hip fracture (n = 113) Vertebral fracture (n = 81) p-value
Age (years), mean ± SD 79.5 ± 9.3 74.6 ± 8.5 <0.01
Height (cm), mean ± SD 152.9 ± 5.9 150.7 ± 6.1 0.015
Weight (kg), mean ± SD 55.0 ± 10.1 55.6 ± 10.8 0.688
BMI (kg/m2), mean ± SD 23.5 ± 4.1 24.4 ± 3.9 0.153
Year of menopause, mean ± SD 28.3 ± 10.5 26.1 ± 8.5 0.156
BMD (T-score), mean ± SD
Spine L1-4 −2.7 ± 1.6 −3.0 ± 1.4 0.383
Femoral neck −3.2 ± 0.9 −3.2 ± 1.0 0.986
Total hip −2.9 ± 1.0 −2.6 ± 1.1 0.149
Co-morbidity (n,%)
Hypertension 72 (63.7%) 42 (51.9%) 0.033
Diabetes 27 (23.9%) 17 (21.0%) 0.634
Stroke 5 (4.4%) 5 (6.2%) 0.742
Parkinson’s disease 2 (1.8%) 1 (1.2%) 1.000
Calcium and Vitamin D containing food (n,%)
Milk 73 (64.6%) 44 (54.3%) 0.149
Yolk 95 (84.1%) 66 (81.5%) 0.773
Cod-liver oil/fatty fish/mushrooms 53 (46.9%) 22 (27.2%) 0.005
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group, there were significantly higher mean i-PTH levels
(45.7 vs. 35.8 pg/mL), lower mean serum calcium (8.2 vs.
8.9 mg/dL), lower mean serum phosphorus (3.5 vs.
4.2 mg/dL) and lower mean BAP levels (13.0 vs. 18.2 mg/
dL) compared to vertebral fracture group (Table 4). Serum
creatinine and alanine aminotransferase were similar be-
tween the groups. The mean vitamin D levels were slightly
higher but no statistical difference in summer and fall than
in winter and spring season.
When analyzing the mean serum 25(OH) D levels and
prevalence using three cut-off points (<30, <20 and <
10 ng/mL) by different age groups (<60; 60 ~ 69; 70 ~ 79;
80 ~ 84; ≥85 years), the results were consistent across all
age groups with no statistical difference in the vitamin D
levels or proportion of patients with vitamin D levels
lower than 30 ng/mL, 20 ng/mL or 10 ng/mL in any of
the age groups (Table 5).Table 2 Distribution of serum 25 (OH) D level in 194
enrolled subjects
n (%) Mean (SD) Range
(Min, Max)
Adequacy [≥30 ng/ml] 26 (13.4%) 37.6 (7.2) (30.0, 57.5)
Inadequacy [<30 ng/ml] 168 (86.6%) 18.6 (6.5) (4.0, 29.7)
Insufficiency [10–30 ng/ml] 151 (77.8%) 20.0 (5.3) (10.0, 29.7)
Deficiency [<10 ng/ml] 17 (8.8%) 6.4 (1.6) (4.0, 9.3)Discussion
This is the first study to examine the prevalence of vitamin
D inadequacy among osteoporotic women with fragility
hip or vertebral fracture in Taiwanese population. The re-
sults of this study have shown a high prevalence of vitamin
D inadequacy (insufficiency and deficiency) across all age
groups among women with fragility hip or vertebral frac-
ture in Taiwan. Some studies conducted in Taiwan and
Asia have shown nearly half of healthy, middle-aged and
elderly women had vitamin D inadequacy, nearly one-
third of adults with frailty syndrome had vitamin D insuffi-
ciency [19,20] and inadequacy levels are more common in
some Asian countries than in other regions [21].
International Osteoporosis Foundation recommends that
a minimum level of 30 ng/mL 25(OH) D is necessary in
older adults to reduce the risk of falls and fractures [15].
Some guidelines suggest a 25(OH) D level of at least 20 ng/
mL to promote intestinal calcium absorption, avoid second-
ary hyperparathyroidism and minimize the risk of fracture
[22]. In our study, the prevalence of vitamin D insufficiency,Table 3 Prevalence of serum 25(OH) D levels using three
cut-off points
<10 ng/ml <20 ng/ml <30 ng/ml
Overall (n = 194) 17 (8.8%) 96 (49.5%) 168 (86.6%)
Hip fracture (n = 113) 12 (10.6%) 60 (53.1%) 99 (87.6%)
Vertebral fracture (n = 81) 5 (6.2%) 36 (44.4%) 69 (85.2%)
NS between fracture types.






Serum 25(OH) D (ng/ml) 20.5 ± 9.9 22.0 ± 8.4 0.279
i-PTH(pg/ml) 45.7 ± 29.2 35.8 ± 19.4 0.005
Calcium (mg/dl) 8.2 ± 0.6 8.9 ± 0.5 0.000
Phosphorus (mg/dl) 3.5 ± 1.0 4.2 ± 2.2 0.004
BAP (mg/dl) 13.0 ± 6.9 18.2 ± 9.3 0.000
Data are expressed as mean ± standard deviation.
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prevalence of 25(OH) D lower than 20 ng/mL was 49.5%.
As compared to the National Health and Nutrition Exam-
ination Survey (NHANES) 2005 to 2006, where 41.6% of
adults had 25(OH) D below 20 ng/mL [23], in the current
study we have found a higher proportion of vitamin D in-
sufficiency (49.5%, vs. 41.6%), probably due to inclusion of
subjects with confirmed fragility fracture either admitted
to hospital or from outpatient clinics and due to exclusion
of patients taking vitamin D supplementation regularly
(2800 IU vitamin D per week or 400 IU vitamin D per
day). The results were consistent with the previous find-
ings that low vitamin D levels were associated with a high
hip fracture rate [24] and other osteoporotic fractures,
including vertebral and wrist fractures [25]. One recent
study has shown that among patients admitted to a re-
habilitation facility, 49.1% had 25(OH) D levels below
20 ng/mL and 83% lower than 30 ng/mL [26], which is
consistent with the current study results. Another study in
the literature has shown 68% of hypo-vitaminosis D in an
orthogeriatric rehabilitation ward within 7 days after hip
fracture [27].
Vitamin D plays an important role in protein synthesis
and the regulation of calcium transport which affects
muscle strength as well as the balance among neurons
and muscle. This might be the reason why vitamin D de-
ficiency has been associated with muscle weakness and
postural instability, leading to an increased risk of falls,
which may lead to fractures [28,29]. Low vitamin D
levels are also associated with decline in physical per-
formance in the elderly [30].
The relationship of 25(OH) D level and i-PTH is con-
sistent with previous reports that the synthesis andTable 5 Mean serum 25(OH) D levels and prevalence in differ
<10 ng/ml <20 ng/ml
<60 y/o (n = 2) 0 (0%) 0 (0%)
60 ~ 69 y/o (n = 36) 3 (8.3%) 17 (47.2%)
70 ~ 79 y/o (n = 64) 4 (6.3%) 33 (51.6%)
80 ~ 84 y/o (n = 41) 3 (7.3%) 24 (58.5%)
≥85 y/o (n = 46) 7 (15.2%) 21 (45.7%)
NS among age groups.metabolism of vitamin D is coupled to calcium homeo-
stasis and is regulated by PTH, serum calcium and phos-
phorus levels [12]. When hypocalcaemia occurs, serum
PTH concentration increases and enhances reabsorption
of calcium. In our study, serum 25(OH) D was inversely
correlated with serum i-PTH (r = −0.22, p < 0.01).
The possible explanations for the high prevalence of
vitamin D insufficiency in this cohort of Taiwanese
women could be several. First, the Recommended Diet-
ary Allowance (RDA) of vitamin D for the elderly is 800
international units per day after age 71 [22], but only
17.5% subjects have vitamin D supplements in daily life
and larger-dose preparations of ergocalciferol or chole-
calciferol are rare in Taiwan. Second, the consumption
of fatty fish, vitamin D-fortified foods and vitamin D
supplements also influence the status of vitamin D insuf-
ficiency [31,32]. This is the largest source of dietary vita-
min D in many countries, but fortified milk, cereals and
bread products with vitamin D in Taiwan are rarely
found. Therefore, vitamin D from dietary source might
be limited due to less options and lower availability of
vitamin D-containing food in addition to decreased in-
testinal absorption of vitamin D in elderly patients.
Third, the vitamin D status depends on the available
amount of ultraviolet light from sunlight which varies
with latitude and season; use of sunscreen and clothing;
and amount of sunlight exposure which increases vita-
min D concentration [33]. Although Taiwan is situated
at latitude between 23 and 25 degrees, sun-avoidance
behavior, skin covering and the use of sunscreen prod-
ucts in the Taiwanese population interfere with produc-
tion of vitamin D in the skin. In addition, the serum
vitamin D level has been shown to decrease with aging,
with the skin of those older than 70 years of age being
less efficient in converting 7- dehydrocholesterol into
vitamin D as compared to younger individuals, impairing
dermal biosynthesis of vitamin D [34].
There are some limitations of the current study. The
sample size of this study (n = 194) was relatively small al-
though well spread and distributed throughout the is-
land. Also, this study did not include healthy subjects
without fractures or male gender as normal controls.
Another limitation was the study design which did not
allow us to collect vitamin D levels at the exact time ofent age groups
<30 ng/ml 25(OH) D level (mean ± SD)
2 (100%) 23.3 ± 1.7
29 (80.6%) 22.5 ± 10.4
61 (95.3%) 20.4 ± 7.9
34 (82.9%) 21.5 ± 10.3
38 (82.6%) 20.2 ± 9.3
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min D would vary significantly in the short period of
time stipulated for blood collection after fracture.
Conclusions
High prevalence of vitamin D insufficiency and defi-
ciency was found among post-menopausal women with
osteoporosis and fragility hip or vertebral fracture in the
Taiwanese population. Recommendations and public
education for postmenopausal women with osteoporosis
to receive adequate vitamin D supplementation should
be reinforced.
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